Cadenza Bio

Cadenza Bio's pipeline of novel, orally available, small molecule drugs have been demonstrated to promote remyelination and limit inflammation in animal models of Multiple Sclerosis. MS is the most widespread disabling neurological condition of young adults. Nearly 1 million patients are living with MS in the U.S., with approximately 15,000 new patients diagnosed each year. There is a clear unmet need related to preventing and slowing the biggest driver of cost – progression of disease to disability and death. While there are several MS drugs available on the market, approved drugs target immune function only. Even with immunomodulatory drugs, patients gradually decline due to progressive damage to the myelin sheath. Cadenza Bio's lead compounds demonstrate proof of concept for remyelination through selective ER-beta agonism in two different animal models of MS. Lead compounds reduce motor disability, increase myelination, and induce neuroprotection in the CNS through promotion of oligodendrocyte precursor differentiation and maturation. Importantly, Cadenza Bio's lead compounds also modulate the immune system in MS to produce an environment that is conducive to myelin repair. Remyelinated fibers are functionally improved as measured by compound action potentials and visual evoked potentials. Further, optic neuritis and visual dysfunction are attenuated in a mouse model of MS. Such measures are commonly used as translational biomarkers of efficacy in MS clinical trials and generally in inflammatory neurodegenerative disease. Cadenza Bio has in vivo proof of concept to support therapeutic efficacy in animal models of Endometriosis, and favorable consideration for use in diseases of neurodegeneration, cognition, and some forms of cancer.